Hyperlipidemic nephropathy induced by adriamycin: effect of melatonin administration

Area of Science:

• Nephrology
• Toxicology
• Biochemistry

Background:

• Adriamycin (AD) is a potent chemotherapeutic agent known to induce significant nephrotoxicity.
• Oxidative stress and free radical damage are implicated in the pathogenesis of AD-induced kidney injury.
• Melatonin (MEL) is a well-known antioxidant with potential protective effects against drug-induced toxicity.

Purpose of the Study:

• To investigate the protective effects of melatonin against Adriamycin-induced nephropathy and oxidative stress in a rat model.
• To evaluate the impact of melatonin on key biochemical markers of kidney function and oxidative damage.
• To assess the efficacy of melatonin in preventing and mitigating AD-induced kidney damage.

Main Methods:

• Wistar male rats were administered a single high dose of Adriamycin (AD).
• Melatonin (MEL) was administered intraperitoneally at specific intervals before and after AD injection.
• Serum and kidney homogenates were analyzed for biochemical parameters including lipids, proteins, urea, creatinine, lipoperoxides, reduced glutathione (GSH), and catalase activity (CAT).

Main Results:

• AD administration led to hyperlipidemia, proteinuria, elevated serum urea and creatinine, and increased lipoperoxides.
• Kidney homogenates showed increased lipoperoxides with decreased GSH and CAT levels following AD treatment.
• Melatonin treatment significantly restored GSH, CAT levels, and reduced proteinuria towards control levels.

Conclusions:

• The findings confirm the role of free radicals in Adriamycin-induced nephrotoxicity.
• Melatonin demonstrates significant antioxidant power and efficacy in preventing and suppressing AD-induced kidney damage.
• Melatonin is a promising therapeutic agent for mitigating Adriamycin-related nephropathy.